Literature DB >> 10779746

The roles of CD28 and CD40 ligand in T cell activation and tolerance.

K C Howland1, L J Ausubel, C A London, A K Abbas.   

Abstract

Costimulation of T cell activation involves both the B7:CD28 as well as the CD40 ligand (CD40L):CD40 pathway. To determine the importance of these pathways to in vitro and in vivo T cell activation, a direct comparison was made of the responses of TCR transgenic T cells lacking either CD28 or CD40L. In vitro, CD28-/- T cells showed a greater reduction in proliferative responses to Ag than did CD40L-/- T cells. The absence of CD28 resulted in defective Th2 responses, whereas CD40L-/- T cells were defective in Th1 development. In vivo, CD28-/- T cells failed to expand upon immunization, whereas CD40L-/- T cells could not sustain a response. These results suggest that CD28 is critical for initiating T cell responses, whereas CD40L is required for sustained Th1 responses. The different functional roles of these costimulatory pathways may explain why blocking B7:CD28 and CD40L:CD40 interactions has an additive effect in inhibiting T cell responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779746     DOI: 10.4049/jimmunol.164.9.4465

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

3.  B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.

Authors:  Ioannis Antonopoulos; Dimitrios Daoussis; Maria-Eleni Lalioti; Theodora E Markatseli; Alexandros A Drosos; Stavros Taraviras; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Rheumatol Int       Date:  2019-06-21       Impact factor: 2.631

Review 4.  Glycogen synthase kinase 3: a point of convergence for the host inflammatory response.

Authors:  Huizhi Wang; Jonathan Brown; Michael Martin
Journal:  Cytokine       Date:  2010-11-23       Impact factor: 3.861

5.  Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.

Authors:  Jiao Wang; Shuangshuang Zheng; Ning Xin; Changxin Dou; Linlin Fu; Xiuying Zhang; Jing Chen; Yanyan Zhang; Deqin Geng; Chenghua Xiao; Guiyun Cui; Xia Shen; Yang Lu; Jinhua Wang; Ruiguo Dong; Yuehua Qiao; Yong Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-17       Impact factor: 4.147

6.  Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.

Authors:  Arno Hänninen; Nathan R Martinez; Gayle M Davey; William R Heath; Leonard C Harrison
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 7.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

8.  Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection.

Authors:  Xuan-Chao Pan; Lei Guo; Ying-Bing Deng; Katsutoshi Naruse; Hiromitsu Kimura; Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

9.  CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals.

Authors:  Jun Liu; Qigui Yu; Geoffrey W Stone; Feng Yun Yue; Nicholas Ngai; R Brad Jones; Richard S Kornbluth; Mario A Ostrowski
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

10.  CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas.

Authors:  Min Xu; Andrew J Lepisto; Robert L Hendricks
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.